Medical form for a patient with malignant melanoma of the skin, made in accordance to the most recent guidelines for diagnosing, treating and monitoring the disease

Authors

  • Strahil Strashilov Department of Plastic Restorative, Reconstructive and Aesthetic Surgery, Medical University Pleven, Bulgaria
  • Veselin Kirov Department of Oncodermatology, Medical University Pleven, Bulgaria
  • Angel Yordanov Clinic of Gynecologic Oncology, Medical University Pleven, Bulgaria
  • Vasil Nanev Department of Surgical Oncology, Medical University Pleven, Bulgaria
  • Miroslava Mihailova Clinic of gastroenterology and hepatology, Medical University Pleven, Bulgaria
  • Ilko Iliev Clinic of Gynecologic Oncology, Medical University Pleven, Bulgaria

DOI:

https://doi.org/10.66344/jpad.28.2.2018.1127

Keywords:

Malignat melanoma, treating, monitoring, medical form

Abstract

The malignant melanoma of the skin is a vary  rare malignant tumor, originating from the epidermal melanocytes. In Bulgaria the average morbidity is 6.5/100000. The tumor affects the younger age and often metastasizes in the early stages of the disease. MM of the skin is also the tumor with the highest rate of increase of morbidity. All of this imposes the usage of an unified tactic for diagnosing, treating and monitoring patients with that disease, aiming to achieve maximized beneficial effect for them, and said tactic to be marked in a fitting, simplified, but understandable, medical form. 

References

Balabanova M, Saleva M; Malignant Melanoma. MedInfo 2016;04:24-29

Wolff K,‎ Johnson R, Fitzpatrick T. Melanoma precursors and primary cutaneous melanoma . Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, 6th edn. Ebook. New York. McGraw Hill Professional; 2009

NCCN Clinical Practice Guidelines in Oncology: Melanoma. 2017. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf

Dummer R, Hauschild A, Lindenblatt N et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: 126–132.

Marsden JR, Newton-Bishop JA, Burrows L et al. Revised UK guidelines of care for the management of cutaneous melanoma. Br J Dermatol. 2010;163:238–256.

Dummer R, Guggenheim M, Arnold AW, et al. Project Group Melanoma of the Swiss Group for Clinical Cancer Research. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly. 2011;5;141:w13320

Pflugfelder A, Kochs C, Blum A, et al. German Dermatological Society; DermatologicCooperative Oncology Group. Malignant Melanoma S3-Guideline “Diagnosis, Therapy and Follow-up of Melanoma†J Dtsch Dermatol Ges. 2013 Aug;11 Suppl 6:1-116, 1-126

Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. 2008. www.nhmrc.gov.au/guidelines/publications/cp111

Downloads

Published

2018-12-13

How to Cite

1.
Strashilov S, Kirov V, Yordanov A, Nanev V, Mihailova M, Iliev I. Medical form for a patient with malignant melanoma of the skin, made in accordance to the most recent guidelines for diagnosing, treating and monitoring the disease. J Pak Assoc Dermatol [Internet]. 2018Dec.13 [cited 2026May3];28(2):245-9. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1127

Issue

Vol. 28 No. 2 (2018): April - June

Section

Surgical Commentary

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.